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Abstract
Background: Drug user networks and community-based organizations advocate for greater, meaningful involvement
of people with lived experience of drug use in research, programs and services, and policy initiatives. Community-
based approaches to research provide an opportunity to engage people who use drugs in all stages of the research
process. Conducting community-based participatory research (CBPR) with people who use drugs has its own ethical
challenges that are not necessarily acknowledged or supported by institutional ethics review boards. We conducted a
scoping review to identify ethical issues in CBPR with people who use drugs that were documented in peer-reviewed
and grey literature.
Methods: The search strategy focused on three areas; community-based research, ethical issues, and drug use.
Searches of five academic databases were conducted in addition to a grey literature search, hand-searching,
and consultation with organizational partners and key stakeholders. Peer reviewed literature and community
reports published in English between 1985 and 2013 were included, with initial screening conducted by two
reviewers.
Results: The search strategy produced a total of 874 references. Twenty-five references met the inclusion
criteria and were included in our thematic analysis. Five areas were identified as important to the ethics of
CBPR with people who use drugs: 1) participant compensation, 2) drug user perspectives on CBPR, 3) peer
recruitment and representation in CBPR, 4) capacity building, and 5) participation and inclusion in CBPR.
Conclusions: We critically discuss implications of the emerging research in this field and provide suggestions
for future research and practice.
Keywords: Scoping review, Community-based participatory research, Ethics, People who use drugs,
Challenges, Incentives, Exclusion, Diversity
Background
Drug user networks and community-based organizations
have underlined the importance of greater, meaningful
involvement of people who use drugs in research,
community programs and services, and policy initia-
tives [1, 2]. Embracing the values of “Nothing About
Us, Without Us” [3], we are called on to acknowledge
histories of research exploitation [4] and to better
engage and support the leadership and involvement of
people who use drugs [5–7].
Conducting community-based participatory research1
(CBPR) in partnership with people who use drugs is one
approach to supporting this engagement strategy, along
with capacity-building among community and academic
partners. CBPR can produce community-relevant results
that are directly applicable to programs, policy, and
practice [8]. CBPR is a collaborative approach to con-
ducting research where multiple stakeholders are equit-
ably involved in all stages of the research process [9]. In
North America, Oceania, Europe, and East and South
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East Asia, we have seen an increase in community-based
research projects that include drug users across a range
of roles from study design, to recruitment, data collec-
tion and analysis, and knowledge dissemination [10].
Alongside the increased use of CBPR are dialogues con-
cerning the ethical challenges with this form of research
[11, 12]. While CBPR shares some aspects of more basic
scientific inquiry, there are marked differences including
approaches that value close connections with community
organizations and participants [13], the engagement of
people with lived experience in recruitment and data col-
lection [14, 15], and data analysis strategies that involve
community members with access (or modified access) to
what may be sensitive and confidential information [16].
Each aspect of these partnerships poses benefits and po-
tential drawbacks and underlines the importance of at-
tending to complicated power dynamics, unequal access
to resources, and differing stakes in the process and out-
comes of the research endeavour [17–19].
Research ethics boards or institutional review boards2
(REBs or IRBs) that were first developed to respond to
the ethical challenges of research in the basic or clinical
sciences continue to expand their understanding of
CBPR and the best strategies to support more ethical
forms of participatory research [20]. Where REBs may
be tasked with gatekeeping roles in more traditional
research, their lack of familiarity with community-based
research may lead them to overemphasize those aspects
of the ethics approval process that are more appropriate
to basic science or clinical trials [21, 22] while overlook-
ing or failing to attend to potential research challenges
in complex community settings and partnerships [20].
The research team for this project is made up of
people who have experience conducting CBPR with
people who use drugs, researchers with experience and
expertise in research ethics, and people who use drugs.
Our goals were to identify ethical issues in community-
based research with people who use drugs that were
documented in the literature and to create a knowledge
dissemination tool to share this information with drug
users and community organizations working with people
who use drugs (for more information on this resource,
see http://drugscbrethics.com). In this paper, we report
on the results of the scoping review, highlighting key
ethical challenges, promising practices, and areas where
further research is recommended. No personal or sensi-
tive data was collected for this project. University of To-
ronto Research Ethics Board deemed this projected not
to require ethics review3
Methods
Scoping review methodology
The methodology for this scoping review followed system-
atic steps to identify, gather, summarize, and integrate
large numbers of individual studies on the topic of CBPR
ethics with people who use drugs. We used Levac, Colqu-
houn, and O’Brien’s [23] definition of a scoping review as,
“a process of summarizing a range of evidence in order to
convey the breadth and depth of a field” [23]. Scoping re-
views allow researchers to rapidly map the key concepts
and the main sources of evidence underpinning the re-
search area [24].
The main steps of this scoping review included an
initial search for relevant peer-reviewed and grey literature,
screening for relevant studies that met pre-determined in-
clusion and exclusion criteria established by the research
team, data extraction, and thematic analysis. Although pre-
sented as a series of steps, the process was iterative, where
some steps were repeated when necessary to ensure that a
broad range of literature was included. Below we
summarize the methodology for this paper in detail using
the Arksey and O’Malley Framework [24].
Framework stage 1: identifying the research
question
The objectives of this scoping review were: 1) to
summarize research findings on CBPR ethics and prac-
tices with people who use drugs; and, 2) to identify gaps
in the existing research literature and opportunities for
future research focused on ethical issues. In order to
meet these objectives, we conducted a scoping review of
empirical studies and grey literature published between
1985 and 2013 to identify published work across various
disciplines pertaining to CBPR ethics with people who
use drugs. We selected 1985 as a starting date due to
the increase in publications related to CBPR after this
time. Our scoping review was guided by the question:
“What ethical issues in CBPR with people who use drugs
are documented in peer-reviewed and grey literature?”
Framework stage 2: identifying relevant studies
Search strategy
In order to identify relevant studies, a computerized
search was conducted of the following databases: 1)
ProQuest (Applied Social Sciences Index and Abstracts,
Biological Sciences: Virology and AIDS Abstracts, Canadian
Research Index, ERIC, ProQuest Research Library, Pro-
Quest Science Journals, PsycARTICLES, PsycCRITIQUES,
PsycINFO, Social Services Abstracts, Sociological Ab-
stracts); 2) Ovid (Ovid MEDLINE, Embase, NASW Clinical
Register, Social Work Abstracts); 3) JSTOR; 4) EBSCO host;
and 5) Cochrane Library. For the current study, all data-
bases were investigated over a 28-year period (1985–2013).
A librarian from the University of Toronto consulted
on the development of our search strategy. The goal was
to identify peer-reviewed and grey literature related to
the ethics of community-based research with people
who use drugs. For convenience, the search terms were
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divided into three foci: 1) for CBPR we selected terms
inclusive to all types of CBPR (e.g., participatory, collab-
orative, action research, community-driven research) in
order to accurately reflect variations in CBPR termin-
ology; 2) in the “drug/substance use” category, terms
were chosen to reflect the diverse nature of people who
use drugs and the substances that may be used (e.g., in-
jection drug use, amphetamines, crack, addiction), and;
3) the terms selected for the domain of “ethics” included
words such as “guidelines”, “principles”, “best practices”,
and “decision-making”. The search terms used are sum-
marized in Table 1.
Hand-searching
When a specific journal was identified as being key to
finding relevant articles, it was hand-searched to identify
articles in the relevant subject areas. In addition, authors
and reference lists from papers identified as relevant
were used to locate further references of interest. Fur-
ther, we conducted an Internet search on Google using
the same search strategy that was used in the academic
databases. Grey literature included research, government
or community reports, but excluded book chapters and
policy documents.
Existing organizations and networks
Additionally, we conducted a literature search (e.g., com-
munity reports) on the following organizational websites:
Canadian Harm Reduction Network (http://canadianharm
reduction.com), Vancouver Area Network of Drug Users
(http://www.vandu.org), CACTUS Montréal (http://www.
cactusmontreal.org), and Drug User Advocacy League
(http://dualottawa.ca).
Framework stage 3: study selection
Inclusion criteria
For the purposes of this scoping review, full-length, empir-
ical research articles and reports focusing on CBPR ethics
with people who use drugs were included. The following
inclusion criteria were identified: 1) published between
1985 and 2013; 2) English language articles from national
and international peer-reviewed or scholarly journals, or
reports dedicated to health, medicine, social sciences, and
interdisciplinary research; 3) articles or reports about drug
use/users; 4) articles or reports on the topic of “ethics” (in-
cluding such diverse aspects of ethics as challenges, com-
pensation, recruitment, wise practices, and empowerment),
and 5) articles/reports on CBPR. References needed to
meet all of the inclusion criteria in order to be included in
the review. Book chapters and policy documents were
excluded from the review.
Further, we excluded biomedical research with people
who use drugs.
Titles and abstracts of all publications were imported
into the data management software, Refworks, and sub-
sequently exported into Excel for screening. First, one of
the authors (RS) conducted the initial appraisal (Level 1
screen), where we identified potentially relevant publica-
tions. If the relevance of the study was not apparent
after review of the article’s title and abstract, the full text
was retrieved for screening in Level 2. During Level 2
screening, full articles and reports were closely examined
and appraised to determine whether they met all pre-
determined inclusion and exclusion criteria (Fig. 1). All
seven authors participated in Level 2 screening, with two
reviewers per article. Disagreements were resolved by a
third reviewer.
Table 1 Search terms
Community based research Drug/substance use Ethics
CBR OR CBPR OR Community-Based Research*
OR Community-based adj2 research*
OR Cooperative behav* OR Community adj2
research* OR Participatory adj2 research*
OR Collaborative research* OR Community-
engaged research* OR Action research*
OR Action Science OR Community Development*
OR Community Organi* OR Community Partner*
OR Community Particip* OR Community-led
research OR Community-led OR User-led adj2
research OR User-led OR Community Collaborat*
OR Collaborative inquiry OR Community
Involve* OR Involving Communit* OR Community
Empower* OR Empowering Communit*
OR Community driven OR Community-driven
OR consumer involve* OR involving consumer
OR community action OR Community-action
Drug use* OR Using drugs OR drug-using OR
drug using OR Substance use* OR substance-
using OR substance using OR Drug abuse*
OR drug-abusing OR Drug misuse* OR user*
OR Substance abus* OR Substance-abusing OR
Drug dependence OR Substance dependen*
OR Addict* OR Drug addict* OR Injection adj2
use* OR Injection use* OR Drug injection*
OR People adj2 inject OR People adj2 drugs
OR Intravenous adj2 use* OR Intravenous adj2
abuse* OR illicit adj2 use* OR Illicit drug*
OR Illicit use* OR PWUID OR PWUID OR people
adj2 crack OR Heroin use* OR Heroin-use*
OR Heroin OR Crack use* OR Crack-use*
OR crack OR Cocaine us* OR Cocaine-using
OR cocaine OR Meth use* OR meth OR
Amphetamine us* OR Amphetamine-us*
OR Amphetamine OR Street drug* OR Needle
shar* OR Needle-shar* OR Needle-exchange
OR Needle exchange OR Parenteral adj2 use*
OR Drug overdos* OR overdos* OR Substance-
related OR Substance related OR Drug-related
OR Drug related
Ethic* OR Ethics code OR Ethical Guidelines
OR ethical standards OR ethical principles
OR moral ethics OR Institutional ethics OR
research ethics OR Bioethic* OR Best Practice*
OR Conduct OR Code adj2 ethics OR Ethical
issue* OR Responsibilit* OR Human Subjects
OR Human Rights OR right* Ethic* adj2
research* OR Principle-based ethics OR
prejudice OR stigma* disadvantage* OR
marginal* OR discriminat* OR trust OR
autonom* OR decision-mak* OR consent*
OR confidential* OR legal liability OR
financial compensation* OR incentive*
OR reimbursement* OR recruitment
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Framework stage 4: charting the data
After the authors conducted a detailed review of the full
text of the article using the inclusion/exclusion criteria
(see above), a data charting process was developed col-
laboratively by the team. Twenty-five references met the
inclusion criteria and proceeded to the data charting
stage. All seven authors participated in the data collec-
tion process. Each author cross-checked charted data
with the other six authors for accuracy. In order to chart
the data, the authors extracted the following information
from the literature: 1) source (author, year of publica-
tion, title, and journal); 2) description of a population
and setting (demographics of study participants, location
of research, type of setting); 3) CBPR-specific character-
istics, such as research procedure, design, recruitment of
participants, data collection and data analysis, and; 4)
Study findings and implications.
Framework stage 5: collating, summarizing, and
reporting the results
The process of collating and summarizing studies was
guided by focusing on the examination of best practices
and challenges when conducting CBPR with people who
use drugs.
The main task involved drawing inferences from the
literature. This followed an inductive analysis and was
closely grounded in our research question. We com-
pared all data and grouped similar concepts (e.g.,
compensation, capacity building, ethical challenges)
from the literature into categories (sometimes one study
fell in more than one category) and differentiated those
concepts from one another. Based on this approach, we
identified themes, which describe the findings we sum-
marized under each category. Peer debriefing was also
employed, in which all of the authors met regularly
to discuss the data analysis process and to resolve
any discrepancies. Five themes presented below were
identified as important to the ethics of CBPR with
people who use drugs.
Results
A total of 897 references were retrieved from the data-
base search, and 5 references from hand searching and
organizational networks. During the initial appraisal we
excluded 28 duplicates. Following this, we excluded 667
publications and identified 207 publications as potentially
relevant (Level 1 screen; Kappa = 0.85). We excluded 667
publications because they did not meet all three inclusion
criteria (e.g., the publication either did not focus on people
who use drugs, and/or did not describe CBPR and/or
ethical aspects of research).
Following this, the 207 publications that met the inclu-
sion criteria based on title and abstract were retrieved
for screening on full text (Level 2 screen; Kappa = 0.94).
During this stage, full articles and reports were closely
examined and carefully appraised for their relevance.
Fig. 1 Flowchart of screening process
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After Level 2 screening, 182 publications were excluded
from our review. Upon closer examination, 78 publica-
tions still did not meet at least two of the three inclusion
criteria and were excluded.
Sixty-eight out of the excluded 182 publications did
not specifically pertain to any ethical aspects of research,
but rather explored topics other than ethical conduct in
research. Twenty-nine of the excluded 182 publications
did not pertain to community-based research or prac-
tice, but rather focused on other forms of research (e.g.,
biomedical or experimental research). The remaining
eleven out of the 182 publications were excluded be-
cause the publications did not focus on people who use
drugs. Only two publications [25, 26] that did not meet
one of the three inclusion criteria (focus on CBPR) were
still included in our review because they were deemed
important by the reviewers and discussed essential as-
pects of research ethics with people who use drugs that
could be easily applied to CBPR.
After the second screen, we were left with a total of 25
publications including 20 from academic databases,
three from hand searching, and two publications from
organizational networks, published between 1985 and
2013, the content of which is presented in Table 2. The
studies reported in the literature were conducted in the
following countries: Canada, the United States, the
United Kingdom, and Australia. Based on the thematic
analysis, we grouped the results into five areas: 1) par-
ticipant compensation and retention, 2) perspectives of
people who use drugs on CBPR, 3) peer recruitment and
representation, 4) capacity building, and 5) participation
and inclusion in CBPR.
Theme 1: participant compensation and retention
in research
Participant compensation garnered most attention in
studies we reviewed. Eight of the 25 included studies ex-
plored the ethics of compensation and incentive pay-
ments. Table 3 presents this literature by the types of
questions raised with regard to fair compensation prac-
tices in research endeavors with people who use drugs.
Within the seven studies on participant compensation
and retention, four studies [27–30] place emphasis on the
importance of fair compensation with cash payments as
opposed to other forms of compensation (e.g., gift cards).
This emerged as the most common topic of discussion in
studies that we reviewed. Within this work, researchers
discussed that not offering incentives and denying rewards
(or offering incentive payments in the form of cash or
vouchers) raises the question of whether drug users are
treated the same way as other participants (or not) simply
because of who they are [28]. One study discussed how
often research ethics committees and boards may require
that investigators not provide remuneration to drug-using
participants, believing that those with a history of drug
use may use study remuneration to buy drugs [30]. The
consensus across studies is that people who (are known
to) use drugs should not be compensated differently than
non-users (e.g., cash when appropriate).
Table 2 Retrieved studies (n = 25)
Theme Citation
Participant compensation
and retention in research
COCQ-SIDA (2012)
Draus et al. (2005) a
Festinger et al. (2008)
Salmon et al. (2010) a
Seddon (2005)
Striley (2011) a
Striley et al. (2008) a
Wolfe and Cohen (2010) a
Drug user perspectives on CBPR Barratt et al. (2007)
Draus et al. (2005) a
Fisher et al. (2008)
Fry and Dwyer (2001)
NAOMI Patients Association and
Boyd (2012)
Singer et al. (2008) a
Wolfe and Cohen (2010) a
Peer recruitment and
representation in CBPR
Baldwin et al. (2009) a
Brown et al. (2005) a
Cunningham-Williams et al. (1999)
Perez et al. (2009)
Rudolph et al. (2010) a
Salmon et al. (2010) a
Shannon et al. (2007) a
Singer et al. (2008) a
Sterk (1999) a
Stewart et al. (2012)
Striley (2011) a
Capacity building Baldwin et al. (2009) a
Brown et al. (2005) a
Salmon et al. (2010) a
Shannon et al. (2007) a
Weeks et al. (2006)
Pragmatics of participation
and social inclusion in CBPR
Aldridge and Charles (2008)
DuBois et al. (2011)
Levine et al. (1991)
Rudolph et al. (2010) a
Salmon et al. (2010) a
Sterk (1999) a
Striley et al. (2008) a
aNote: study classified under more than one theme
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Two publications [31, 32] discuss the importance of
effective communication with regards to various prac-
tical issues (e.g., rules) surrounding the compensation of
research participants who use drugs. Here, publications
discuss how effective communication by research orga-
nizations about the use of incentives to all relevant
stakeholders in the community is essential [31], and
should take place at the start of the research [28].
Three studies [28, 29, 33] explored how compensating
participants with cash (as opposed to other forms of
compensation) improves both the quality of research
and the retention of people who use drugs in research.
Research showed that neither the amount of compensa-
tion nor the mode of payment (cash or gift card) had a
significant effect on new drug use among clients in an
outpatient substance abuse treatment program; instead,
individuals receiving cash (vs. gift cards) were more
likely to use their payments for essential, non-luxury
purchases [33]. Further, one publication [27] provided a
discussion of the benefits of using cash payments over
other types of remuneration, including the suggestion
that the use of cash as payment for participation affirms
the non-judgmental stance of the research project, maxi-
mizes the appeal of research participation, and mini-
mizes the traceability of incentives (thereby protecting
confidentiality).
Within this theme, four publications provided explicit
recommendations. Striley [30] proposed asking partici-
pants what benefit they seek from participating in a
community-based study (as any understanding of remu-
neration or benefit must be population-specific), and
what remuneration they perceive as appropriate. Salmon
and colleagues [32] suggest that the rules for what type
of work receives honorarium and its amount should be
fair and ensure that opportunities to receive compensa-
tion are clearly identified and equally divided among
participants. Similarly, two publications [28, 31] recom-
mend that effective communication by research organi-
zations about the use of incentives to all relevant
stakeholders in the community is essential and should
take place at the beginning of the research.
Theme 2: how people who use drugs view
research practices
Six out of 25 publications highlight the nuances of how
people who use drugs view research practices. These
studies included discussions regarding participants’ per-
spectives and motivations to participate in research, and
how past experiences influence participant views on re-
search initiatives with people who use drugs. The overall
findings in two publications [34, 35] were that motiva-
tions for participation in research are multi-dimensional,
including a desire to provide and share information or
expertise; participate in informed decision-making; ex-
press opinions; contribute to solving drug problems;
help without consideration of personal gain; dispel
myths about drug users; and improve services for drug
users [35]. Similarly, another study [34] showed that
when injecting drug users were asked to nominate the
best and worst aspects of participating in research, bene-
fits to others (assisting fellow drug users, provision of in-
formation, policy contributions) and personal benefits
(cash payments, opportunities to talk and share experi-
ence) were identified as positive factors.
Table 4 reports various environmental and institu-
tional factors, which were identified as negative aspects
of participating in research by people who use drugs or
as barriers to involvement of people who use drugs in
research. Six publications explored the concerns of
people who use drugs when participating in research.
Three publications focused specifically on CBPR prac-
tices [27, 34, 36], while one publication focused on clin-
ical trials with people who use drugs [25]. One
publication [34] described the negative factors that hin-
der drug user involvement in research and identified
how personal discomfort with research, inconvenience,
and risk work as participation barriers for people who
use drugs. Two studies [27, 37] highlighted that in places
(e.g., smaller towns), where treatment programs and
local criminal courts may be directly affiliated, research
participants raise concerns that the information about
ongoing drug use could be shared with treatment agen-
cies and somehow make its way to law enforcement.
Table 3 Research focus in studies discussing participant
compensation and retention
Citation Focus
COCQ-SIDA [31] The importance of effective communication
with regards to compensation in research.
Draus et al. [27] The benefits of using cash payments
(as opposed to other forms of compensation)
to remunerate participants in research.
Festinger et al. [33] The benefits of incentive payments to
increase the quality of survey answers and
facilitate access to people who are normally
harder to reach.
Salmon et al. [32] The importance of clarifying rules for what
type of work receives honorarium (and its
amount).
Seddon [28] The decision-making process by researchers
who do not offer compensation based on
the assumption that participants use
research incentives to purchase illegal drugs.
Striley [29] The benefits of cash payments to increase
the retention of people who use drugs in
research.
Striley et al. [30] The decision-making process by researchers
and research ethics boards who do not
compensate people who use drugs for their
time with cash.
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Similar concerns with regard to experimental mistrust,
fears of exploitation, and objectification at the hands of
investigators are voiced by people who use drugs when
participating in randomized control trials [25]. This
theme was also salient in a community report [4], which
describes how participants often link research with their
personal experience of unfavorable and exploitative
medical care, and distrust of clinical researchers. One
study [34] identified perceived lack of impact of research
findings as one of the worst things about research pro-
jects, and highlighted the importance of better commu-
nication by investigators as to how a study aims to
impact policies and practices to the benefit of drug-user
communities.
Theme 3: peer recruitment and representation in
CBPR
Overall, peer recruitment is presented as a useful ap-
proach in six out of the 25 publications we reviewed [29,
38–42]. Various forms of peer recruitment are com-
monly recommended to improve enrolment of diverse
samples of drug users to broaden the composition of
participants in CBPR, including social network tracking
and the utilization of peer referrals [38]; employing peers
within a community as outreach workers [39]; recruit-
ment through community partners (e.g., staff at local
pharmacies) [40]; the use of community-peer hiring
panels [41]; and the use of “translators” (i.e., individuals
familiar with the cultures and language of street-involved
active drug users, as well as academic researchers) [42].
Two publications [29, 39] clearly articulated that peer re-
cruitment can reach community members using an in-
sider approach, accessing more hard-to-reach groups, and
increasing the generalizability of CBPR.
However, studies also cautioned researchers about the
problematic consequences of using peer recruitment.
For instance, one study [38] suggested that peer workers
tend to successfully recruit drug users with social char-
acteristics similar to their own. Another study [29]
highlighted that the peer-recruitment approach can also
be harmful to communities, as it can increase the risk of
coercion when it is used without developing sustainable
community partnerships, without proper support for
communities, or when it poses threats to the confidenti-
ality or privacy of participants.
Further, an important element in a subset of the CBPR
studies we reviewed is their emphasis on ensuring the
voices of diverse members of drug user communities are
represented in research practices. Overall, six out of 25
studies (citations listed in Table 3) highlighted the im-
portance of attending to the socio-cultural nuances,
norms, and needs of diverse communities of people who
use drugs. It is important to note that only six publica-
tions included descriptions of participants and provided
contextual information on the participants’ background
(e.g., demographic factors or other socio-cultural aspects
of communities of people who use drugs). Table 5 repre-
sents some of the diverse groups of participants in these
studies.
In terms of challenges specific to CBPR research with
distinct communities, the studies reviewed highlight the
importance of taking into account their norms, history,
and cultural location. For example, research with Latino
and Hispanic people who use drugs identified the fol-
lowing ethical challenges in CBPR, including loss of con-
fidentiality, stigma related to HIV or drug use, fear of
family or community rejection, as well as misconcep-
tions and stereotypes [36]. A study with African-
American cocaine users in rural Arkansas [42] described
community-researcher collaborations, and suggested the
importance of training “translators” – individuals who
were well versed in the experiences of African-American
cocaine users in rural communities, and those who
understand the lived realities of people who use drugs
and maintain consistently open avenues of communica-
tion between community members and researchers.
Similarly, research with Indigenous communities in
the U.S. (American Indian and Alaska Native communi-
ties) illustrates the benefits of CBPR (collaborative
relationships, development of programs in culturally
acceptable ways, disseminating research findings from
Indigenous perspectives), but also reminds researchers
how important it is to be aware of and sensitive to the his-
tory of relationships before a community is approached
[43]. In a similar fashion, another study [44] suggests that
CBPR can be a valuable tool for determining the immedi-
ate concerns of prisoners, such as the receipt of high-
quality and dignified health care inside and outside
Table 4 Negative aspects of research participation, as identified
by people who use drugs
Citation Negative aspects of research
Barratt et al. [34] Discomfort with research; inconvenience;
risk; perceived lack of impact of research
findings.
Barratt et al. [34] Confidentiality and safety concerns, in
particular due to criminalization of drug
use.Draus et al. [27]
Wolfe and Cohen [37]
Singer et al. [36]
Barratt et al. [34] Mistrust of experiments; fears of
exploitation and objectification at the
hands of investigators.Fisher et al. [25]
NAOMI and Boyd [4]
Singer et al. [36] Stigma related to HIV/AIDS or drug use;
fear of family or community rejection;
misconceptions and stereotypes about
drug users.
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prisons (as this population bears significantly higher rates
of Hepatitis C, HIV, tuberculosis, and other physical con-
ditions). From a research ethics perspective, this work
highlights that in building research agendas researchers
must be sensitive to the priorities of marginalized popula-
tions and ensure the participation of communities
impacted by the resulting policies.
Four publications focused specifically on the lives of
women who use drugs [32, 41, 44, 45]. One study [44]
identified that female prisoners tend to have lower in-
comes, lower educational levels, and higher rates of
mental illness and substance abuse issues than women
in the non-prison population. This study [44] also sug-
gested in pursuing CBPR, it is essential to consider the
critical ethical question regarding how to ensure that
women engaged in CBPR truly benefit from this process.
Another study with substance-using women [41] ex-
amined the HIV-related vulnerabilities, barriers to acces-
sing care, and the impact of current prevention and
harm reduction4 strategies among women in survival sex
work. This study highlights the concern of ensuring
privacy and confidentiality for all participants, both of
which require particular consideration in the context of
drug use and sex work. Finally, one study [45] provided
examples of the barriers and best practices associated
with different steps in community-based collaborations
with women who inject drugs. These scholars highlight
the importance of overcoming stereotypes, treating each
person with dignity, praising accomplishments, develop-
ing a “trusted” presence in the drug-user community,
frank discussions among collaborators, and acknowledg-
ing different agendas as a means to overcome communi-
cation barriers among stakeholders in community-based
collaboration.
Theme 4: capacity building and CBPR
Five publications [32, 41, 43, 45, 46] out of the 25 that
we reviewed focused on capacity building among people
who use drugs and suggested that individuals who use
drugs who participate in research-related activities
(especially those who are affiliated with community-
based agencies) should be offered employment, salaries,
recognition, training, opportunities to participate in
decision-making, and other types of support. Few arti-
cles contained descriptions of, or recommendations for,
capacity building with drug users not already connected
with community-based organizations/agencies.
For staff capacity building within drug user communi-
ties, one study [41] suggests that community-based agency
staff should be compensated for all evaluation and
research-related activities. They should be offered salaries
and opportunities to publish while sharing the decision-
making process, as it is inappropriate to expect commu-
nity members to serve in volunteer roles when academic
researchers receive salaries to conduct studies. More spe-
cifically, with regards to opportunities like employment,
the literature recommends employing people who use
drugs in both key roles at community-based agencies [32]
and low-threshold employment positions, which work
from a harm reduction perspective [45]. The project by
Shannon and colleagues [41] described the capacity build-
ing process, where a team of substance-using women with
lived experience of survival sex work was hired, trained,
and supported to play an active role in guiding, develop-
ing, and conducting the research.
Another study [43] discussed engaging women who
use drugs in paid employment and training them as peer
interviewers on the CBPR project. This study suggested
that the perspectives and knowledge gained by employ-
ing peer researchers/interviewers enhanced the capacity
of the research team as well as the type of knowledge
gained, while the research training provided the peer in-
terviewers with skills and income that enhanced their
capacity for engaging in future research, organizational
development, and community action [43].
In another study [46] researchers provided training to
people who use drugs as peer public health advocates
(PHA), to bring a structured, peer-led intervention into
sites where participants and their peers and drug-using
social networks use drugs. This study identified that bar-
riers for PHAs to complete their training included home-
lessness, and arrests for drug-related or other charges,
such as theft, trespassing or loitering [46]. This study [46]
also provided a recommendation to researchers and policy
makers that they take into account the ways homelessness,
as well as arrests for drug-related or other charges, are sig-
nificant barriers for marginalized people who use drug to
complete training and gain employment.
Theme 5: pragmatics of participation and
inclusion in CBPR
Nine of the 25 publications discuss the pragmatics of the
inclusion of people who use drugs. Specifically, two pub-
lications [6, 39] describe the benefits of including people
Table 5 Socio-demographic characteristics of participants in
several CBPR studies with people who use drugs
Citation Population
Baldwin et al. 2009 [43] American Indian, Alaska Native communities
Brown et al. 2005 [45] Women who inject drugs
Perez et al. 2009 [44]
Salmon et al. 2010 [32]
Perez et al. 2009 [44] Prisoners who use drugs
Shannon et al. 2007 [41] Substance-using women in survival sex work
Singer et al. 2008 [36] Latino and Hispanic people who use drugs
Stewart et al. 2012 [42] African-American cocaine users in rural U.S.
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who use drugs in CBPR. According to one study [39] the
involvement of people who use drugs in community-
based research may result in the inclusion of culturally ap-
propriate questions, a sampling design that is reflective of
the community needs, and findings that take community
contexts and lived experiences into consideration. Further,
the literature suggests that the benefits of including people
who use drugs (in particular people who inject drugs) in
CBPR research can be empowerment, increased tolerance
of drug using behaviours, reduction of stigma, and in-
creased social support networks [40].
When the topic of exclusion is discussed, three publica-
tions highlight (and at times critique) how and why re-
searchers exclude participants who use drugs who are
deemed too intoxicated to participate in research (Table 6).
One study [26] suggests that excluding injection drug
users from clinical trials is unacceptable unless there is
strong evidence to support exclusion (e.g., threat to
safety). Another study [47] critiques how researchers
sometimes exclude intoxicated participants when they are
deemed “too intoxicated” to participate. Finally, a third
study [30] highlights how many researchers often exclude
people from their studies who test positive for illicit sub-
stance use, based on reasons such as possible non-
compliance with research protocols (e.g., follow-up ap-
pointments), even though research suggests that the use
of CBPR to enroll people who use drugs can achieve a
95 % retention rate [30].
Only two publications [32, 48] gave specific recom-
mendations concerning how to increase the inclusion of
people who use drugs in CBPR. One study [32] critiqued
the class-based and ableist biases implicit in some CBPR
projects, such as, that all partners must demonstrate
equitable participation by remaining actively involved in
all phases of the research process. Instead, researchers
recommended accommodating people in research who
want to participate at different times and in ways that
shift in accordance with their health status, drug use pat-
terns (and consequences), housing concerns, and other
aspects of their lives. Similarly, one study [48] suggested
that while many members from a community may wish
to engage with researchers, available resources limit the
number of community members who can be engaged.
As such the recommendation is that CBPR researchers
should always remain critical and reflexive of how many,
and which individuals from the community, are provided




Participant compensation was the ethical issue most
commonly addressed in the literature included in this
scoping review, and a consensus emerged that people
who use drugs should not receive lesser compensation
(or restrictive compensation, such as gift cards) solely
because they are known to use drugs non-medically.
However, these articles identified the need for clear com-
munication with communities and potential participants
about compensation, given that active drug users often
live in extreme poverty and thus compensation practices
perceived to be unfair can be particularly problematic.
Under the theme of perceptions of people who use drugs
related to research, studies suggested that people who
use drugs often participate in research for altruistic rea-
sons or to help their own communities, in addition to
potential personal benefits. Perceived negative aspects of
participation often related to fear of research related
risks, and concerns about the whether the research
would have real-world positive impacts. Taken together,
these findings point to the importance of ensuring that
research projects balance risks and benefits to communi-
ties of people who use drugs, as well as individual people
who use drugs, and that community-level as well as indi-
vidual risks and benefits are clearly considered and
communicated.
Peer recruitment and representation was another the-
matic area that emerged, the latter primarily in relation
to Indigenous peoples and communities of color in the
United States, but also women, sex workers, and pris-
oners. Peer recruitment was viewed as integral to
recruiting large and diverse samples of people who use
drugs, but also presented ethical challenges regarding
support for recruiters, coercive recruitment, and partici-
pant confidentiality.
Under the theme of capacity building, low-threshold
and flexible employment and training for people who
use drugs was identified as an important component of
ethical CBPR practice. Finally, studies related to prag-
matics of participation and inclusion in CBPR suggested
that excluding people from research on the basis of drug
Table 6 Examples of justifications for exclusion of people who
use drugs from research
Citation Justification for exclusion
Aldridge and Charles
2008 [47]
Describes assumptions held by researchers that
exclusion is justified if a participant is deemed
“too intoxicated” to participate (based on
biochemical or bio-behavioural screening).
DuBois et al. 2011 [48] Describes how financial resources may limit the
number of community members who can be
included or involved in research.
Levine et al. 1991 [26] Suggests there is strong evidence to support
exclusion if a drug-using participant is ‘a threat
to safety’.
Striley et al. 2008 [30] Describes assumptions held by researchers
that exclusion is justified because participant
may become non-compliant with research
protocols or follow-up appointments
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use at the time of recruitment is usually unethical, but
that inclusion needs to be balanced with the ability to
give informed consent while under the influence of
drugs.
Reflections on successful CBPR projects with people
who use drugs led to recommendations for flexible and
accommodating practices that are responsive to the oft-
chaotic living conditions of low-income people who use
drugs, so that individuals are not entirely excluded
from study involvement if they are deemed (or deem
themselves) unable to participate at a particular time.
Such practices may help to resolve the ethical and
pragmatic dilemmas that arise from policies regarding
study participation for people who are actively or cur-
rently using drugs.
Research gaps
The 25 articles included in this scoping review addressed
issues relevant to the nexus of ethics, CBPR, and people
who use drugs in five thematic areas. However, we found
no studies explicitly focused on ethical issues in the con-
text of community-based participatory research with
people who use drugs5. Moreover, few studies addressed
ethical issues specific to community-based participatory
research with people who use drugs. Given the recent
proliferation of resources specific to peer involvement in
CBPR, this is a noteworthy gap. Themes that were most
specific to CBPR with people who use drugs (e.g., capacity
building) often focused on their involvement as peer re-
cruiters or study staff. Yet, most community members will
be involved in a CBPR study primarily as participants.
Nevertheless, a CBPR approach raises additional ethical
dimensions across all levels of involvement (e.g., around
personal disclosure to peer researchers, intra-community
conflicts) [11, 17, 19]. While these topics are becoming
more visible in the body of work related to community-
based research ethics, they are unaddressed in the
reviewed literature specific to research with people who
use drugs. Most studies were conducted in or focused on
Canada, Australia, the United Kingdom, and the United
States, and thus additional knowledge is needed regarding
ethical issues for CBPR with people who use drugs in set-
tings where drug use is more or less criminalized or stig-
matized (e.g., in the few countries or regions that have
decriminalized some or all personal drug use, as well as in
settings where drug-related offenses are punishable by
forced “treatment”, corporal punishment, or death).
Limitations of our approach
While our search terms were developed in consultation
with a research librarian and selected to include the
broad scope of terms used in the literature, there may
have been relevant peer-reviewed articles that were not
captured by these terms. In addition, our search of the
grey literature was not exhaustive or systematic.
Conclusions
Many ethical issues pertaining to CBPR are common
across marginalized populations. For instance, CBPR
with people who use drugs may be similar to CBPR en-
deavors with other marginalized groups with respect to
ethical imperatives and challenges to community en-
gagement and sustained involvement. However, this
scoping review revealed some unique ethical consider-
ations for CBPR with people who use drugs that have
been under-addressed to date. With respect to the prag-
matics of inclusion and exclusion in research, Aldridge
& Charles [47] address the ethical imperative to ensure a
balance between protecting the autonomy of people who
use drugs (who may be more likely to consent when in-
toxicated) and justice in relation to extending the bene-
fits of research participation. However, their
recommendations explicitly assume that intoxication is
“relatively transitory”, and thus, it is unclear how they
might apply to people who use drugs on a daily basis. In
addition, no specific guidelines exist for the bio-
behavioural assessment and screening of intoxicated par-
ticipants, partially because both biochemical and behav-
ioural methods for identifying intoxication are
problematic. Instead, researchers should seek to devise
research protocols that acknowledge intoxication and
protect research participants by offsetting risks and po-
tential harms to participants [47]). More empirical re-
search is needed to understand the complexities of
consent for people who use drugs frequently or daily. In
addition, policies and practices that exclude the most in-
toxicated individuals may, consciously or not, result in
research findings that do not reflect the realities of those
most at-risk of poor health and social outcomes, and
may limit their access to material and other benefits of
CBPR (compensation, training, peer support).
Articles included in this scoping review did not dir-
ectly address competing or unclear definitions of “com-
munity” that might complicate the ethical engagement
of people who use drugs in CBPR. For example, there
are many clearly documented benefits of involving both
active users and former users in various types of health
promotion efforts, as well as the substantial role of
former users in drug user treatment and research [42,
46]. Elsewhere, Roy [12] distinguishes between CBPR
with people who use drugs versus CBPR about drug use
with non-using members of minority communities; these
divergent approaches to research were not distinguished,
or possibly conflated, in some articles (e.g., [43]). At
issue in this distinction is whether drug use is treated as
a behaviour, or as a characteristic that, at least in some
cases, defines an identifiable community that must be
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engaged in community-based research about drug use.
These questions reflect broader discussions and tensions
concerning definitions of community in the context of
CBPR [49, 50], which have specific implications in the
context of drug use. For example, under the theme of
capacity building, most articles assumed that people
who use drugs would be engaged in research through
community health organizations that they are affiliated
with (e.g., HIV/AIDS service organizations, community
health centres), or that the organizations themselves
would be the “community” research partners. Yet, such
organizations are typically staffed and directed by people
who do not identify as active drug users. Where they
exist, it seems that drug user-led networks and organiza-
tions would be well-suited to represent community
interests in research. However, such groups may require
additional support, time, training, and material resources
in order to participate in research; they may also have
more explicitly political aims and activities that conflict
with some researcher agendas. We believe that more at-
tention should be paid to defining and mobilizing com-
munities of people who use drugs, with an ethical
orientation towards supporting drug user self-organizing
(recognizing that participation in research may help
fledgling organizations to develop capacity) [7, 51, 52].
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1Community-based participatory research (CBPR) is a
term used throughout this paper. Other variations of this
term (with their own distinctions) include: community-
based research (CBR), Community-Engaged Research
(CEnR), and action research (see Wallerstein and Duran
[8] for further background).
2Other variations of the term Research Ethics Board
(REB) are Research Ethics Committee (REC), and Insti-
tutional Review Board (IRB) – the latter term primarily
used in the USA.
3This project did not require research ethics review
under the guiding document for research in Canada –
known as Tri-Council Policy Statement (TCSP2). TCPS2
article 2.5 provides an exemption for activities that do
not meet the threshold for the Canadian definition of re-
search but may use techniques similar to those
employed in research. For example, quality assurance,
program evaluation activities and other activities used
exclusively for assessment, management or improvement
purposes – such as the activity we did. No personal or
sensitive data was collected through these consultations.
University of Toronto Research Ethics Board was con-
sulted and they deemed this projected not to require
ethics review.Given that this project did not meet the
definition of research and was minimal risk, the consul-
tants form the communities were informed verbally
about the nature of their involvment. The team decided
not to collect any personal nor sensitive information
given that collecting that information may put commu-
nity consultants in harm's way and expose them to risk.
4Harm reduction is a non-punitive, pragmatic approach
to drug use, which acknowledges that people engage in
behaviors that may harm their health, and seeks to reduce
these harms [45].
5One study was published since our search: Strick-
land JC, Stoops WW. Perceptions of research risk
and undue influence: Implications for ethics of re-
search conducted with cocaine users. Drug Alcohol
Depend. 2015. doi: 10.1016/j.drugalcdep.2015.09.029.
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